Cutaneous T-cell lymphoma

5 trials MedDRA PT
5 Registered trials
0 Recruiting
4 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Antibody-drug conjugate (ADC) 1 substance
Phase III: 1 Phase I: 3 Phase I (First in Human): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    BRENTUXIMAB VEDOTIN
    2025-521093-34-00 1 country n=84
    Pending

Phase I

3 trials
  • Kyowa Kirin Inc. Commercial
    IMP not specified
    2025-522523-96-00 2 countries n=34
    Pending
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-520294-13-00 2 countries n=35
    Pending

Phase I (First in Human)

1 trial
  • Taiho Oncology Inc. Commercial
    TOLINAPANT LACTATE
    2024-516679-33-00 2 countries 2017 n=16
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Assistance Publique Hopitaux De Paris Academic 2 Phase I, Phase III 0
Kyowa Kirin Inc. Commercial 1 Phase I 0
Seagen Inc. Commercial 1 Phase I 0
Taiho Oncology Inc. Commercial 1 Phase I (First in Human) 0
New trials by year
2024
1
← All indication landscapes